FHTX
NASDAQFoghorn Therapeutics Inc.
Price$3.68-1.95 (-34.64%)
2026-03-052026-06-08
News · 26 weeks39-91%
2025-12-142026-06-07
Mix1890d
- Other9(50%)
- SEC Filings8(44%)
- Insider1(6%)
Latest news
25 items- PRFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Goldman Sachs 47th Annual Global Healthcare Conference 2026 Fireside Chat: Tuesday, June 9, 2026, at 1:20 p.m. EDTPresenter: Adrian Gottschal
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
- PRFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in MayWATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. H.C. Wainwright
- SECSEC Form 10-Q filed by Foghorn Therapeutics Inc.10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRFoghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million; cash runway into the first half of 2028 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
- SECSEC Form DEFA14A filed by Foghorn Therapeutics Inc.DEFA14A - Foghorn Therapeutics Inc. (0001822462) (Filer)
- SECSEC Form DEF 14A filed by Foghorn Therapeutics Inc.DEF 14A - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRFoghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer - Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy - Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a c
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- INSIDERSEC Form 4 filed by Gottschalk Adrian4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- PRFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingNew preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and po
- SECSEC Form S-8 filed by Foghorn Therapeutics Inc.S-8 - Foghorn Therapeutics Inc. (0001822462) (Filer)
- SECSEC Form 10-K filed by Foghorn Therapeutics Inc.10-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRFoghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic OutlookFHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026 Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL) Completed a $50 million registered direct financing in January 2026 Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of the January 2026 financing, the company has cash runway into the firs
- INSIDERSEC Form 4 filed by Chief Financial Officer Maynard Ryan D4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 3 filed by new insider Maynard Ryan D3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- PRFoghorn Therapeutics to Participate in Two Upcoming Investor ConferencesWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. TD Cowen 46th Annual Health Care Conference Presentation: Tuesday, March 3, 2026, at 11:10 a.m. EDTPresenter: Adri
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial OfficerWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. "I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, Pres
- ANALYSTJefferies resumed coverage on Foghorn Therapeutics with a new price targetJefferies resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00
- INSIDERSEC Form 4 filed by Chief Executive Officer Gottschalk Adrian4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
FHTX FAQ
7 questionsWhat does Foghorn Therapeutics Inc. do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with...Where does FHTX stock trade?
Foghorn Therapeutics Inc. (FHTX) is listed on NASDAQ.What sector and industry is FHTX in?
Foghorn Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Foghorn Therapeutics Inc. go public?
Foghorn Therapeutics Inc. (FHTX) completed its IPO in 2020.What are analysts saying about FHTX?
Foghorn Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1200.00 price target on 2026-02-17. Recent price targets range from $900.00 to $2000.00.What companies are similar to FHTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FHTX side-by-side with any of them on Quantisnow.How can I track FHTX on Quantisnow?
Quantisnow aggregates Foghorn Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FHTX to receive live email and push alerts on every new disclosure.